REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > O-glycoside > > Nitrogen Containing Hetero Ring Nitrogen Containing Hetero RingNitrogen Containing Hetero Ring patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027095 - Nicotinamide riboside kinase compositions and methods for using the same The present invention relates to isolated nicotinamide riboside kinase (Nrk) nucleic acid sequences, vectors and cultured cells containing the same, and Nrk polypeptides encoded thereby. Methods for identifying individuals or tumors susceptible to nicotinamide riboside-related prodrug treatment and methods for treating cancer by administering an Nrk nucleic acid sequence or ... 02/01/07 - 20070027094 - Inhibitors of nitric oxide synthase The current invention discloses novel methods for the inhibition of inducible nitric oxide synthesis (iNOS) and the production of NO. Methods of inhibiting the induction of proinflammatory cytokines are also described. Methods of treating various disease states, such as X-linked adrenoleukodystrophy, multiple sclerosis, Alzheimer's and septic shock using inhibitors of ... 01/18/07 - 20070015720 - Modulation of endogenous aicar levels for the treatment of diabetes and obesity The invention relates to methods for treating type 2 diabetes, obesity, metabolic syndrome and conditions associated with these by administering an AICAR-monophosphate (AICAR-MP) enhancing agent that increases endogenous AICAR-MP levels in a cell. Inhibition of AICAR-formyltransferase activity (AICARFT) in a cell that regulates metabolic activity (such as fat, liver, muscle, ... 01/04/07 - 20070004654 - Methods of treating gastrointestinal inflammation The present invention provides methods of treating gastrointestinal inflammation, methods of treating inflammatory bowel disease, methods of treating Crohn's Disease, and methods of treating ulcerative colitis in an individual. The methods generally involve administering an effective amount of an agent that increases the level of a Type I interferon and/or ... 12/07/06 - 20060276419 - Combined use of ribavirin and interferon beta in demyelinating diseases in combination with an interferon (IFN) for the manufacture of a medicament for treatment and/or prevention of a demyelinating disease. In particular, it relates to the use of a combination of Ribavirin and IFN-beta for treatment and/or prevention of a demyelinating disease, such as multiple sclerosis. ... 11/23/06 - 20060264390 - Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B ... 11/23/06 - 20060264389 - Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase Thee present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA via replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B ... 11/09/06 - 20060252715 - Tricyclic-nucleoside compounds for treating viral infections Disclosed are compounds represented by formulae I, II, and III, and the compositions and methods thereof for treating viral infections caused by a Flaviviridae family virus. ... 11/02/06 - 20060247189 - Forms of 5-azacytidine The invention also includes pharmaceutical compositions comprising said forms. ... 11/02/06 - 20060247188 - Effective treatment of tumors and cancer with triciribine and related compounds The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat tumors and cancer by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of ... 10/26/06 - 20060241065 - Ring-expanded nucleosides and nucleotides The present invention relates to compositions comprising analogues of purine nucleosides containing a ring-expanded (“fat”) heterocyclic ring, in place of purine, and an unmodified or modified sugar residue, pharmaceutically acceptable derivatives of such compositions, as well as methods of use thereof. In particular, these compositions may be utilized in the ... 10/26/06 - 20060241064 - Nucleoside compounds for treating viral infections Disclosed are compounds, compositions and methods for treating viral infections caused by a Flaviviridae family virus, such as hepatitis C virus. ... 10/26/06 - 20060241063 - Novel uses of neuraminidase inhibitors in infectious diseases The present invention relates to methods of decreasing the infectivity, morbidity and rate of mortality, in treating diseases associated with a variety of pathogenic organisms, specifically diseases involving one or more pathogens that require neuraminidase as a virulence factor. In addition, the present invention uses biology based therapy to treat ... 10/26/06 - 20060241062 - Method involving pde4, compositions, and the screening thereof, for the treatment of degenerative ocular pathologies The invention relates to the field of biology, genetics and medicine. In particular, the invention relates to novel methods for the detection, characterization and/or treatment (or management) of neurodegenerative pathologies. The invention also relates to methods for the identification or screening of compounds active in the aforementioned pathologies. The invention ... 10/19/06 - 20060234963 - Hepatitis c therapies The invention provides methods for treating hepatitis C viral infections and related viral infections, as well as compounds and compositions that are useful for treating such infections. ... 10/19/06 - 20060234962 - Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B ... 10/12/06 - 20060229265 - Nicotinamide riboside and analogues thereof Provided herein are sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular ... 10/12/06 - 20060229264 - Crystalline 6-n-pyridylmethylaminoindolocarbazole compounds wherein R is an unsubstituted pyridyl methyl group or a pyridyl methyl group substituted by a hydroxy methyl group; or a pharmaceutically acceptable salt or a solvate thereof. ... 09/14/06 - 20060205687 - Azacytosine analogs and derivatives Compounds and compositions of azacytosine analogs and derivatives are provided. In one aspect of the invention, analogs or derivatives of decitabine and azacitidine are provided with modification at the 2-, 4-, or 6-position of the triazine ring, at the 1′-6′position of the ribose ring, or combinations thereof. Methods of using, ... 09/14/06 - 20060205686 - Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B ... 09/14/06 - 20060205685 - Azacytosine analogs and derivatives Compounds and compositions of azacytosine analogs and derivatives are provided. In one aspect of the invention, analogs or derivatives of decitabine and azacitidine are provided with modification at the 4- and 6-position of the triazine ring, at the 1′-6′position of the ribose ring, or combinations thereof. Methods of synthesizing and ... 09/07/06 - 20060199776 - Novobiocin analogues as anticancer agents Novel analogues and derivatives of novobiocin are provided, including compounds having modifications to the amide side chain, coumarin ring, and sugar moieties. The compounds of the present invention are useful as heat shock protein 90 inhibitors, and may be used as anticancer and neuroprotective agents. ... 08/31/06 - 20060194749 - Tricyclic-nucleoside prodrugs for treating viral infections Disclosed are compounds, compositions and methods for treating viral infections caused by a Flaviviridae family virus, such as hepatitis C virus. ... 08/17/06 - 20060183699 - Vaccines containing ribavirin and methods of use thereof Compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans are disclosed. More particularly, vaccine compositions comprising ribavirin and an antigen, preferably an antigen that has an epitope present in Hepatitis C virus (HCV), are disclosed for use in treating ... 08/10/06 - 20060178322 - Methods for indentifying compounds that modulate an enzyme involved in riboflavin metabolism in a pathogenic microorganism A method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in a metabolic pathway by inhibiting the conversion of substrate to produce the penultimate or ultimate product particularly by inhibiting the activity of one or more of the enzymes in the pathway, and ... 08/10/06 - 20060178321 - Methods for indentifying compounds that modulate an enzyme involved in reductive carboxylation in a pathogenic microorganism A method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in a metabolic pathway by inhibiting the conversion of substrate to produce the penultimate or ultimate product particularly by inhibiting the activity of one or more of the enzymes in the pathway, and ... 08/10/06 - 20060178320 - Methods for indentifying compounds that modulate an enzyme involved in thiamine metabolism in a pathogenic microorganism A method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in a metabolic pathway by inhibiting the conversion of substrate to produce the penultimate or ultimate product particularly by inhibiting the activity of one or more of the enzymes in the pathway, and ... 08/10/06 - 20060178319 - Caprazene as novel compound and derivatives thereof, and caprazol as novel compound and derivatives thereof and a caprazol-1′″-amide-3′″-ester derivative and a caprazol-3′″-ester derivative, etc. from caprazol. Furthermore, an imidazolidinone derivative could be synthesized from the ring-opened product of the 1,4-diazepinone ring of caprazol. The novel caprazene derivative, novel caprazol derivative and novel imidazolidinone derivative now synthesized exhibit excellent antibacterial activities against a variety of bacteria, ... 06/22/06 - 20060135448 - Hydroxypyridinones for the local treatment of skin microcirculatroy disorders The application of hydroxypyridonone in effective amounts as external agent for patients suffering from skin micro-circulatory disorders (SMD) provides for a significant amelioration of subject conditions. Accordingly, the new use of hydroxypyridonones as external anti-inflammatory agent thereby combined with the depletion of hemosiderin residues offers a suitable treatment to SMD ... 06/15/06 - 20060128643 - Compositions containing a combination of a creatine compound and a second agent The present invention relates to the use of creatine compound and neuroprotective combinations including creatine, creatine phosphate or analogs of creatine, such as cyclocreatine, for treating diseases of the nervous system. Creatine compounds in combination with neuroprotective agents can be used as therapeutically effective compositions against a variety of diseases ... 05/25/06 - 20060111311 - 5-nitro-nucleoside compounds for treating viral infections Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. ... 05/18/06 - 20060105972 - Method to enhance delivery of glutathione and atp levels in cells A therapeutic method is provided comprising treating a mammal subject to hypoxia with an amount of 2(R,S)-D-ribo-(1′,2′,3′,4′-tetrahydroxybutyl)thiazolidine-4(R)-carboxylic acid (RibCys) or a pharmaceutically acceptable salt thereof effective to both maintain, restore or increase both the ATP levels and the glutathione (GSH) levels in said tissue. ... 05/04/06 - 20060094671 - Compositions of treating hepatitis virus infections with n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, or ... 05/04/06 - 20060094670 - Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases wherein A is a nitrogen-, oxygen-, or sulfur-linked aryl, alkyl, cyclic, or heterocyclic group, the group being further substituted with an electron contributing moiety; B is hydrogen, or a halogen, amino, or thiol group; C is hydrogen, or a halogen, amino, or thiol group; and D is a primary alcohol, ... 04/27/06 - 20060089319 - Method for treatment and prevention of bacterial vaginosis Methods for treatment and prevention of bacterial vaginosis are described. In order to treat a patient diagnosed with bacterial vaginosis, an antibiotic is administered to the patient and all infected participant-partners. Bacterial vaginosis is prevented in a human patient planning to participate in activities in which the patient's vagina may ... 04/27/06 - 20060089318 - Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases The present invention provides compounds having the formula: (I); Also provided are pro-drug compounds of the formula: (II); The invention also provides pharmaceutical compositions containing the above compounds, methods of using the above compounds as pharmaceuticals, and processes for preparing the above compounds. Methods for inhibiting an ADP-ribosyl transferase, ADP-ribosyl ... 04/20/06 - 20060084616 - Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases, and uses thereof wherein A is chosen from a nitrogen-, oxygen-, or sulfur-linked aryl, alkyl, cyclic, or heterocyclic group; both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen; and D is a primary alcohol, a ... 04/13/06 - 20060079468 - Nucleoside compounds for treating viral infections Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. ... 03/16/06 - 20060058250 - Methods of treating proliferative skin diseases using carbazole derivatives The present invention relates to a method of treating a proliferative skin disease, comprising administering a therapeutically effective amount of a trk inhibitor. ... 03/16/06 - 20060058249 - Efficient nucleic acid encapsulation into medium sized liposomes A method for preparing liposomes containing at least one nucleic acid encapsulated therein comprising the following steps: (A) mixing a gel or a liquid containing gel particles with aqueous medium Z1 to directly form the liposomes containing the at least one nucleic acid encapsulated therein; (B)(i) mixing a gel or ... 02/16/06 - 20060035848 - Broad-spectrum inhibitor of viruses in the flaviviridae family The present invention relates generally to the fields of chemistry and molecular biology. More particularly, it concerns the use of compounds to treat viral infection. In a preferred embodiment, 2-amino-8-(β-D-ribofuranosyl) imidazo [1,2-a]-s-triazine-4-one may be used to treat infection by viruses of the Flaviviridae family. ... 02/02/06 - 20060025359 - Composition and method for treating graft-versus-host disease Compositions and methods are provided for prevention and clinical treatment of various forms of graft-versus-host disease (GVHD) by using inhibitors of adenosine deaminase (ADA). In particular, various formulations and dosing regimens of ADA inhibitors such as pentostatin are provided for the treatment of all forms of GVHD, especially steroid-refractory acute ... 01/12/06 - 20060009401 - Method for treatment and prevention of herpes zoster by topical application wherein X represents a halogen atom. ... 01/05/06 - 20060003951 - Anti-viral 7-deaza l-nucleosides The present invention comprises 7-deaza L-nucleosides having unexpectedly high inhibitory activity against the hepatitis B virus. The invention further comprises pharmaceutical compositions comprising such compounds as well as methods of treating mammals, particularly humans, infected with HBV and other viral infections. ... 12/29/05 - 20050288240 - Novel-prodrugs for phosphorus-containing compounds M is selected from the group that attached to PO32−, P2O63−, or P3O94− is a biologically active agent, and is attached to the phosphorus in formula I via a carbon, oxygen, sulfur or nitrogen atom; and pharmaceutically acceptable prodrugs and salts thereof. ... 12/08/05 - 20050272676 - Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B ... 12/08/05 - 20050272675 - Methods for isolating crystalline form i of 5-azacytidine The invention also includes pharmaceutical compositions comprising Form I of 5-azacytidine. ... 12/01/05 - 20050267056 - Synthesis and manufacture of pentostatin and its precursors, analogs and derivatives Methods and compositions are provided for efficiently preparing and manufacturing pentostatin. Also provided are novel precursors of pentostatin, pentostatin analogs and derivatives. In one aspect of the invention, a method is provided for total chemical synthesis of pentostatin via a route of heterocyclic ring expansion. For example, a heterocyclic pharmaceutical ... 11/24/05 - 20050261211 - Process for preparing substituted benzimidazole compounds The invention relates to new methods of preparing substituted benzimidazole compounds, such as 2-bromo-5,6-dichlorobenzimidazole, which are useful in the preparation of compounds having antiviral activity. ... 11/17/05 - 20050256066 - Fredericamycin derivatives The invention relates to novel fredericamycin derivatives, to drugs containing said derivatives or the salts thereof, and to the use of the fredericamycin derivatives for treating diseases, especially cancer diseases. ... 10/27/05 - 20050239726 - Novel nucleosides and related processes, pharmaceutical compositions and methods The invention provides novel nucleosides and related processes, pharmaceutical compositions, and methods. The novel nucleosides are useful in a wide variety of antiviral, antineoplastic, and antibacterial applications. Preferred embodiments of the instant invention include novel 2 halogen-substituted, 3 halogen-substituted, and 2′,3′dihalogen-substituted analogues of 3-deazaadenosine, and novel 3 halogen-substituted analogues of ... 10/20/05 - 20050233989 - Flavin n-oxides: new anti-cancer agents and pathogen eradication agents Compounds comprising flavin N-oxides for treatments of solid tumors, non-solid tumor masses, leukemias, and non-small cell lung cancers and for eradicating contaminants in blood products. Methods of treating patients having solid type cancers comprising administering a therapeutically effective amount of a flavin N-oxide to a subject in need of treatment ... 10/20/05 - 20050233988 - Novel compounds a pharmaceutically acceptable salt thereof, or a prodrug thereof. ... 10/20/05 - 20050233987 - Novel therapeutic use of riboside of 5-aminoimidazole-4-carboxamide (acadesine) Acadesine (also known as AICA riboside or AICAR) does not inhibit apoptosis in lymphocytes, as it might be expected, but it induces apoptosis in B cells from patients with B-cell lymphoproliferative disorders such as B-cell chronic lymphocytic leukemia (B-CLL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), follicular lymphoma ... 10/06/05 - 20050222056 - Heterocyclic compounds and their use in the detection of nucleic acids The invention concerns compounds of the general formula (I) in which the residues R1 to R7 have the meanings given in the application as well as methods for their preparation. The compounds are in particular suitable as substrates for RNA or DNA polymerases and can thus be incorporated into RNA ... 09/22/05 - 20050209176 - Compounds that interact with kinases A method of inhibiting or effecting the activity of protein kinase activity which comprises contacting a protein kinase with a compound of formula (I) being a derivative of a furanose or pyranose form of a monosaccharide, or a pharmaceutically acceptable salt thereof. ... 09/22/05 - 20050209175 - Idraparinux(sanorg34006)for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis The invention relates to a dose of 2.5 mg of the pentasaccharide methyl O-(2,3,4-tri-O-methyl-6-O-sulfo-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-β-D-glucopyranosyl uronic acid)-(1→4)-O-(2,3,6-tri-O-sulfo-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-α-L-idopyranosyl uronic acid)-(1→)-2,3,6-tri-O-sulfo-α-D-glucopyranoside or a pharmaceutically acceptable salt thereof for use in therapy, in particular for the treatment and/or secondary prophylaxis of venous thromboembolic events in patients with deep venous thrombosis. ... 08/25/05 - 20050187172 - Combination of a cox-2 inhibitor and a dna topoisomerase i inhibitor for treatment of neoplasia The present invention provides combinations of a Cox-2 inhibitor and a DNA topoisomerase inhibitor and methods of use thereof for preventing and/or treating neoplasia or or a neoplasia-related disorder in a subject. ... 08/25/05 - 20050187171 - Glycomimetic antagonists for both e-and p-selectins Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics linked to a member of a class of ... 08/18/05 - 20050182001 - 3-beta-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and uses thereof The invention is directed to 3-β-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds. ... 08/11/05 - 20050176658 - Method of using protease inhibitors for the treatment of liposarcomas Liposarcomas are treated using HIV protease inhibitors, particularly nelfinavir. The protease inhibitors may be used alone or in combination with traditional cancer treatments, such as chemotherapy, radiotherapy, or surgery. ... 08/04/05 - 20050171038 - Therapeutic combinations The present invention relates to methods for treating an HIV infection a mammal by administering to the mammal a therapeutically effective amount of a combination of compounds. The present invention also relates to compositions comprising certain compounds useful as inhibitors of the HIV protease enzyme and at least one additional ... 08/04/05 - 20050171037 - Therapeutic combinations The present invention relates to methods for improving the pharmacokinetics of certain compounds useful as inhibitors of the HIV protease enzyme by inhibiting the enzyme activity of cytochrome P450. The present invention also relates to compositions comprising certain compounds useful as inhibitors of the HIV protease enzyme and at least ... 08/04/05 - 20050171036 - Use of antitumor indolopyrrolocarbazole derivative and other anticancer agent in combination R1 and R2 each independently represent a hydrogen atom, lower alkyl, or the like, and G represents pentosyl or the like, X1 and X2 each independently represent a hydrogen atom, a halogen atom, or the like or a pharmaceutically acceptable salt thereof; and a preparation, in combination with a pharmaceutically ... 07/28/05 - 20050164960 - Methods of inhibiting orthopoxvirus replication with nucleoside compounds The present invention provides methods of inhibiting orthopoxvirus replication and/or treating orthopoxvirus infection with certain nucleoside compounds and derivatives thereof. These compounds are particularly useful as inhibitors of vaccinia virus and variola virus replication and/or for the treatment of vaccinia virus and variola virus infection. The nucleoside compounds may be ... 07/21/05 - 20050159372 - Nucleoside analogs with carboxamidine modified monocyclic base Novel nucleoside analog compounds are disclosed. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects ... 07/14/05 - 20050153908 - Use of ribofuranose derivatives against inflammatory bowel diseases wherein R is a group selected from a carboxamide, an amidine, and pharmaceutically acceptable acid addition salts thereof, and the configuration at the C2 carbon of the ribofuranose moiety is D or L. The one or more ribofuranose derivatives (I) may be used in combination with further active agents such ... 07/14/05 - 20050153907 - Use of ribofuranose derivatives against inflammatory bowel diseases wherein R is a group selected from a carboxamide, an amidine, and pharmaceutically acceptable acid addition salts thereof, and the configuration at the C2 carbon of the ribofuranose moiety is D or L. The one or more ribofuranose derivatives (I) may be used in combination with further active agents such ... 07/07/05 - 20050148524 - Compositions and methods for the treatment of cancer This invention relates to compositions comprising thalidomide and another anti-cancer drug which can be used in the treatment or prevention of cancer. Preferred anti-cancer drugs are topoisomerase inhibitors. A particular composition comprises thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and irinotecan. The invention also relates to methods ... 07/07/05 - 20050148523 - Method of treating hiv infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor A method of treating HIV infection in a human patient wherein the infecting HIV strain has become resistant to atazanavir, the method comprising administration of a therapeutically effective amount of a combination of atazanavir or a pharmaceutically acceptable salt thereof, and at least one other HIV protease inhibitor. A method ... 06/30/05 - 20050143329 - Indole antiviral compositions and methods The present invention provides novel chemical compounds, and methods for their use. In particular, the present invention provides indole derivatives (e.g. as shown in Formula (I)) and related compounds and methods of using indole derivatives and related compounds as therapeutic agents to treat a number of conditions, including those associated ... 06/23/05 - 20050137150 - Forms of 5-azacytidine The disclosure also includes pharmaceutical compositions comprising said forms. ... 06/23/05 - 20050137149 - Methods and compositions for regulating imidazoline receptors The present invention relates to methods and compositions for regulating the activity of imidazoline receptors. In particular, the invention relates to pharmaceutical compositions comprising imidazoleacetic acid-ribotide (IAA-RP), imidazoleacetic acid-riboside (IAA-R) and its related congeners such as pros-linked ribotide and riboside. The invention is based on the discovery that IAA-RP and ... 06/16/05 - 20050130915 - Polymorphic antiviral nucleoside compounds The present invention relates to the polymorphic crystalline hydrochloride salts of a nucleoside valinate ester according to formula Ib, methods of treating diseases mediated by Hepatitis C Virus and pharmaceutical composition containing Ib. ... 06/09/05 - 20050124563 - Triazole linked carbohydrates Disclosed is an invention concerning triazolyloligosaccharides, oligosaccharides wherein the bonding between the saccharide groups is via a triazole group and methods for their preparation. ... 06/09/05 - 20050124562 - Bis-quinazoline compounds for the treatment of bacterial infections Bis-quinazoline compounds based on the compound (3,4-Dihydro-quinazolin-2-yl)-quinazolin-2-yl-amine, and methods of use of the compounds as inhibitors of bacterial DNA polymerase holoenzymes and in the treatment of bacterial infections are described. ... 06/02/05 - 20050119200 - Nucleoside derivatives for treating hepatitis c virus infection Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. ... 06/02/05 - 20050119199 - Method of stabilizing reduced nicotinamide adenine dinucleotide or reduced nicotinamide adenine dinucleotide phosphate It is an object of the present invention to provide a method of stabilizing reduced nicotinamide adenine dinucleotide or reduced nicotinamide adenine dinucleotide phosphate [hereinafter abbreviated as NAD(P)H] and a preparation containing NAD(P)H stabilized by the method. As the method of stabilizing NAD(P)H, a method of adding astaxanthin to NAD(P)H ... 06/02/05 - 20050119198 - Novel target to inhibit angiogenesis The invention relates to the field of angiogenesis. In particular the invention relates to the use of molecules binding to prominin-1 that can be used for the manufacture of a medicament to prevent pathological angiogenesis. ... 06/02/05 - 20050119197 - Naadp analogues for modulating t-cell activity A method for modulating T cell activity by modulating the intracellular concentration and/or activity of NAADP+, compounds capable of modulating the effect of NAADP+ on T cell Ca2+ levels, and methods for identifying the same, are described. ... ### FreshPatents.com Support |